Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - A new approach to coronary artery disease

Expert Opinion on Investigational Drugs

Volumn 13, Issue 10, 2004, Pages 1365-1368

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Cholesteryl ester transfer protein; Clinical trial; HDL cholesterol; JTT 705; LDL cholesterol; Torcetrapib

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; CLOFIBRIC ACID; CORONARY ARTERIOSCLEROSIS; GLYCOPROTEINS; HUMANS; QUINOLINES;

EID: 5444220762     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.10.1365     Document Type: Article

References (10)

1. BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. (2004) 350: 1505-1515.
2. DOGGRELL SA: Statins in the 21st century: end of the simple story? Expert Opin. Investig. Drugs (2001) 10: 1755-1766.
3. GENEST JJ, McNAMARA JR, SALEM DN, SCHAEFER EJ: Prevalence of risk factors in men with premature coronary artery disease. Am. J. Cardiol. (1991) 67: 1185-1189.
4. RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341: 410-418.
5. RUBINS HB, DAVENPORT J, BABIKIAN V et al.: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation (2001) 103: 2828-2833.
6. GEORGE STEINER AND DIABETES ATHEROSCLEROSIS INTERVENTION STUDY INVESTIGATORS: Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet (2001) 357: 905-910.
7. BARTER PJ, BREWER HB Jr, CHAPMAN MJ et al.: Cholesteryl ester transfer protein - a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (2003) 23: 160-167.
8. OKAMOTO H, YONEMORI F, WAKITANI K et al.: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 46: 203-206.
9. DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - a randomized Phase II dose-response study. Circulation (2002) 105: 2159-2165.
10. GOTTO AM Jr: High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am. Heart J. (2002) 144(6 Suppl.): S33-S43.